Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2007 1
2008 1
2009 1
2011 1
2014 2
2015 1
2016 1
2017 6
2018 4
2019 3
2020 2
2021 1
2022 1
2023 2
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

21 results

Results by year

Filters applied: . Clear all
Page 1
Minimal residual disease in chronic lymphocytic leukaemia.
García Vela JA, García Marco JA. García Vela JA, et al. Med Clin (Barc). 2018 Feb 23;150(4):144-149. doi: 10.1016/j.medcli.2017.06.067. Epub 2017 Aug 31. Med Clin (Barc). 2018. PMID: 28864095 Review. English, Spanish.
CD105 expression in early erythroid precursors.
García-Vela JA, Martin Rubio I, Marquet J, Alvarez Juarez MA. García-Vela JA, et al. Am J Hematol. 2017 Aug;92(8):E155-E156. doi: 10.1002/ajh.24763. Epub 2017 Jun 1. Am J Hematol. 2017. PMID: 28403526 Free article. No abstract available.
Clonal T lymphocytosis resolution after adalimumab discontinuation.
Alonso Trillo R, García Vela JA. Alonso Trillo R, et al. Med Clin (Barc). 2024 Apr 26;162(8):402-403. doi: 10.1016/j.medcli.2023.11.006. Epub 2023 Dec 1. Med Clin (Barc). 2024. PMID: 38042734 English, Spanish. No abstract available.
Genomic mutation profile in progressive chronic lymphocytic leukemia patients prior to first-line chemoimmunotherapy with FCR and rituximab maintenance (REM).
González-Rincón J, Garcia-Vela JA, Gómez S, Fernández-Cuevas B, Nova-Gurumeta S, Pérez-Sanz N, Alcoceba M, González M, Anguita E, López-Jiménez J, González-Barca E, Yáñez L, Pérez-Persona E, de la Serna J, Fernández-Zarzoso M, Deben G, Peñalver FJ, Fernández MC, de Oteyza JP, Andreu MÁ, Ruíz-Guinaldo MÁ, Paz-Arias R, García-Malo MD, Recasens V, Collado R, Córdoba R, Navarro-Matilla B, Sánchez-Beato M, García-Marco JA. González-Rincón J, et al. Among authors: garcia vela ja. PLoS One. 2021 Sep 10;16(9):e0257353. doi: 10.1371/journal.pone.0257353. eCollection 2021. PLoS One. 2021. PMID: 34506616 Free PMC article.
High prognostic value of measurable residual disease detection by flow cytometry in chronic lymphocytic leukemia patients treated with front-line fludarabine, cyclophosphamide, and rituximab, followed by three years of rituximab maintenance.
García-Marco JA, Jiménez JL, Recasens V, Zarzoso MF, González-Barca E, De Marcos NS, Ramírez MJ, Parraga FJP, Yañez L, De La Serna Torroba J, Malo MDG, Ariznavarreta GD, Persona EP, Guinaldo MAR, De Paz Arias R, Llanos EB, Jarque I, Valle MDCF, Tatay AC, De Oteyza JP, Martin EMD, Fernández IP, Martinez RM, Costa MAA, Champ D, Suarez JG, Díaz MG, Ferrer S, Carbonell F, García-Vela JA; GELLC Study Group. García-Marco JA, et al. Among authors: garcia vela ja. Haematologica. 2019 Nov;104(11):2249-2257. doi: 10.3324/haematol.2018.204891. Epub 2019 Mar 19. Haematologica. 2019. PMID: 30890600 Free PMC article.
21 results